Financial Data and Key Metrics Changes - The company's Q2 2025 revenues were $25.9 million, representing a 4% decrease from $27 million in Q2 2024, which included a $2.8 million revenue loss from the non-renewal of the Chicago contract [16][17] - Gross profit for Q2 2025 was $13.8 million, or 53% of revenue, compared to $16.1 million, or 60% of revenue in the prior year [17] - Adjusted EBITDA was $3.4 million in Q2 2025, down from $5.1 million in Q2 2024, reflecting delayed contracts and increased costs [17][18] - GAAP net loss was approximately $3.1 million, or a loss of $0.25 per share, compared to a net loss of $800,000, or a loss of $0.06 per share in the prior year [20] Business Line Data and Key Metrics Changes - The company launched ShotSpotter Live in four new cities and expanded in four additional cities during Q2 2025, contributing to a diversified pipeline of over $37 million for the remainder of 2025 [5][6] - The SafePoint pipeline is healthy, with a focus on healthcare and casino verticals, particularly in California due to the AB 2,975 initiative [25] - The integration of the PlateRanger LPR solution with CrimeTracer enhances investigative capabilities, allowing for quicker access to actionable intelligence [9][10] Market Data and Key Metrics Changes - The company is expanding its footprint in South America, with notable deployments in Niteroi, Brazil, and Montevideo, indicating growth opportunities in Latin America [26][27] - The healthcare vertical is expected to benefit from California's new legislation mandating weapon screening capabilities at state hospitals [11] Company Strategy and Development Direction - The company is focused on transforming into a broader public safety technology firm, emphasizing sustainable growth and operational execution [4] - Strategic investments in technology, innovation, and market positioning are yielding positive results, with plans to deepen penetration in existing customer accounts and expand into mid-size municipalities [14][15] - The company is also exploring new opportunities in critical infrastructure protection, particularly with a sniper detection solution aimed at utility companies and financial institutions [6][42] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver lifesaving alerts and critical crime intelligence, positioning itself well despite potential political changes [12] - The company reaffirmed its full-year revenue guidance of $111 million to $113 million and adjusted EBITDA margin guidance of 20% to 22% [23] - The annual recurring revenue (ARR) is expected to increase from $95.6 million in 2025 to approximately $110 million in 2026, despite the loss of revenue from the Chicago contract [23] Other Important Information - The company ended Q2 2025 with $9 million in cash and cash equivalents, down from $11.7 million at the end of Q1 2025, but cash balance has since increased to over $16 million [20][21] - The company repurchased 31,570 shares at an average price of $14.84, totaling approximately $1.5 million [21] Q&A Session Summary Question: Can you talk about the SafePoint pipeline? - The SafePoint pipeline continues to grow, focusing on healthcare and casino verticals, with significant opportunities in California [25] Question: How is the international market developing? - Recent developments in South America, particularly in Brazil, are promising, with opportunities for expansion in Mexico and South Africa [26][27] Question: What contributed to the increase in cash balance? - The increase is primarily due to timing in receivable collections, indicating strong cash flow generation [28] Question: How much visibility is there into the second half revenue guidance? - The sales team has committed to contracts that should help meet guidance, but timing of large contracts may affect results [30] Question: Can you provide details on the Chicago RFP? - The company is on a shortlist for the Chicago RFP, with a live demonstration scheduled for September, indicating progress in the selection process [54] Question: What are the details regarding the NYPD contract? - The NYPD contract involves a $400,000 expense per quarter, with a revenue of about $250,000 per quarter, leading to overall savings [56] Question: When can the company expect revenue from the SafePoint implementation? - Revenue from the SafePoint implementation is included in the guidance, and the company is working to expedite deployment [48][50]

Financial Data and Key Metrics Changes - Revenue for Q2 2025 was $9 million, down from $9.3 million in Q2 2024, primarily due to lower transient volumes influenced by adverse weather and fewer special events [17][19] - Net Operating Income (NOI) decreased by 3.5% year over year to $5.4 million, attributed to lower transient volumes [19] - Adjusted EBITDA was $3.8 million, down about 6% from $4.1 million in the prior year, with an adjusted EBITDA margin of 42.8% [20] Business Line Data and Key Metrics Changes - Contract parking grew, with monthly contracts increasing by 2.5% during the quarter and over 6.5% year to date, particularly strong in residential monthly contracts, which rose by 44% since year-end [7][8] - Transient pricing saw a year-over-year increase, reflecting the positioning of garages and the ability to drive rates even in a lower volume environment [6] Market Data and Key Metrics Changes - Portfolio level utilization was slightly below last year's levels, with declines concentrated in three markets due to construction and development activities [11] - In Cleveland, contract revenue increased nearly 30% year over year, driven by residential and traditional office contracts [9] Company Strategy and Development Direction - The company is focused on an asset optimization strategy aimed at unlocking $100 million from non-core assets over three years, with $20 million in active negotiations for asset sales [16] - The strategy includes redeploying proceeds into select parking assets to enhance net operating income potential [16] Management's Comments on Operating Environment and Future Outlook - Management noted that while the second quarter faced challenges, the long-term value of assets is expected to improve as construction projects conclude and demand drivers return [5][14] - The company anticipates that the second half of 2025 will see business trends similar to the first half, with potential seasonal tailwinds from increased event attendance and hotel occupancy [25] Other Important Information - The company has maintained a stable balance sheet with total debt outstanding at $214 million, flat compared to the previous year [21] - The published NAV is $7.25 per share, indicating a material discount relative to the stock price [22][23] Q&A Session Summary Question: What are the parameters of the $20 million potential dispositions? - The company is not disclosing the number of properties but expects pricing to be similar to previous asset sales at significant multiples of parking income [31] Question: How are you planning to address the line of credit maturity? - The company is evaluating refinancing options and is confident in working with supportive lenders to manage the maturity [32] Question: How does the guidance flow through to EBITDA? - The company has significant operating leverage and is focused on monthly contracts, with strong cost controls in place to drive NOI [34] Question: What is the transient performance outlook for Q3? - Transient performance in Q2 improved over Q1, but was impacted by weather and construction, with expectations for improvement as construction concludes [36][37] Question: Can you clarify the contract parking trend? - Contract parking demand is slightly slower than expected, particularly in residential areas, but long-term trends remain positive [42][43] Question: Is there significant competition for the assets in the market? - There is significant demand for parking assets, with various buyers interested, providing the company with optionality [50]

Financial Data and Key Metrics Changes - In Q2 2025, revenues increased to $303,000 from $89,000 in the same period last year, representing a 240% increase primarily due to a contract manufacturing agreement on BioCosaceuticals [8] - The loss from operations for Q2 2025 was $3.3 million, compared to $2.5 million for the same period in 2024 [9] - The net loss for Q2 2025 was $2.7 million or $0.30 per share, compared to a net loss of $4 million or $0.50 per share for 2024 [9] - The company ended the quarter with cash, cash equivalents, and marketable securities of $7.4 million and no outstanding debt [9][20] Business Line Data and Key Metrics Changes - The lead clinical stage candidate, BRTX-100, is in a Phase 2 trial for chronic lumbar disc disease (CLDD), with promising preliminary data showing over 74% of subjects achieving greater than 50% improvement in function and over 72% reporting greater than 50% reduction in pain by 52 weeks [12][13] - The enrollment for the BRTX-100 trial is progressing well, with more than halfway through the goal of 99 subjects [14] - The core preclinical metabolic program, THERMACEM, is focused on developing cell-based therapies for obesity and metabolic disorders, with ongoing discussions for potential licensing agreements [15][16] Market Data and Key Metrics Changes - The company is in advanced discussions with key partners to accelerate the growth of its regenerative biologic secretone products [17] - The market for secretone products is significant, and the company aims to achieve high margins in this business [30] Company Strategy and Development Direction - The company is focused on advancing its two core clinical development programs, BRTX-100 and ThermoStem, while ramping up commercial opportunities in regenerative biologics [17] - There is a strategic emphasis on obtaining FDA approval for BRTX-100 and exploring various indications for future trials [22] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism regarding the regulatory environment and the progress of the BRTX-100 trial, highlighting a strong safety profile and encouraging trends in efficacy [19][41] - The company is committed to efficiently managing cash reserves while executing strategic goals, with expectations of a potential reduction in SG&A expenses as enrollment stabilizes [28][20] Other Important Information - The company has been methodically building a comprehensive portfolio of issued patents to protect its metabolic disease programs [15] - Management noted that the FDA's support for stem cell therapies could facilitate an expedited regulatory pathway for BRTX-100 [37] Q&A Session Summary Question: Timing for the start of the CCDT trial and its size - The company did not comment on the cervical trial but emphasized the focus on the lumbar trial and its progression towards a BLA [22] Question: Revenue growth expectations for Cosmoceutical - Management indicated that while growth is expected, it is difficult to predict exact quarterly performance due to the nature of the growing business [24] Question: SG&A expense trends - Management confirmed that SG&A expenses are expected to follow a similar trend as last year, with heavier expenses in the first quarter and lighter in subsequent quarters [26] Question: Recent interactions with the FDA regarding expedited pathways - Management noted anecdotal support from the FDA for an accelerated pathway but did not disclose any new designations beyond the fast track designation [38] Question: Comparison of Phase 2 trial results to placebo - The primary endpoint is safety, with a minimum requirement of 30% improvement in pain and function compared to baseline and a control group [40][41] Question: Potential for unblinded interim data - Management suggested that discussions with the FDA could shape the regulatory strategy, potentially allowing for an interim analysis [43]

PSQ Holdings (PSQH) Q2 2025 Earnings Call August 12, 2025 04:30 PM ET Speaker0Thank you for standing by. My name is Eric, and I'll be your conference operator today. At this time, I would like to welcome everyone to the Public Square Second Quarter twenty twenty five Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer session.I would now like to turn the call over to Will Kent, Senior Vice President of ...

Financial Data and Key Metrics Changes - Revenue grew by 5.5% on a constant currency basis and reported revenue was up 8.5% compared to the prior year [10] - Net loss decreased to $3.9 million from $76.6 million in the previous year, primarily due to lower general and administrative expenses [10][23] - Adjusted EBITDA was $9.7 million, down from $20.4 million in the same quarter of 2024 [11][22] - Adjusted earnings per share was $0.07 compared to $0.18 in the prior year [23] Business Line Data and Key Metrics Changes - Paid content revenue grew by 2% on a constant currency basis, driven by strength in Japan, while declines were noted in Korea and the rest of the world [14] - Advertising revenue increased by 10.2% on a constant currency basis, with growth in Korea and Japan, but a decline in the rest of the world [15] - IP Adaptations revenue surged by 42.6% year on year on a constant currency basis, with significant contributions from Korea [16] Market Data and Key Metrics Changes - In Korea, revenue grew by 9.2% year over year on a constant currency basis, with MAU decreasing by 11.1% [18] - Japan saw revenue growth of 5.7% year over year, with MAU increasing by 2.8% [19] - The rest of the world experienced a revenue decline of 4.4% year over year, driven by declines in paid content and advertising [20] Company Strategy and Development Direction - The company is focusing on enhancing user experience through significant product updates and expanding its library with popular titles [6][7] - A partnership with Disney was announced to bring iconic comics to the platform, which is expected to drive user growth and engagement [7][31] - The company aims to maintain investment in marketing to drive future growth while improving product offerings [24] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, citing strong user engagement and the potential for monetization through new content and platform upgrades [9][24] - The company anticipates revenue growth in Q3 2025 in the range of 9.4% to 12.2% on a constant currency basis [24] - Management acknowledged challenges from external factors, such as government bans affecting user metrics, but remains focused on long-term growth strategies [12][68] Other Important Information - The company is experiencing a decline in overall MAU, primarily due to the impact of Wattpad, but is optimistic about future growth in this area [12][68] - Gross profit for the quarter increased by 5.1% to $87.3 million, with a gross margin of 25.1% [21] Q&A Session Summary Question: Impact of Disney partnership on user growth and monetization - Management highlighted the strategic significance of the Disney collaboration, emphasizing the potential for accelerated user growth and engagement without immediate financial impact [31][32] Question: Marketing arrangements related to the Disney partnership - Management noted the importance of reaching Gen Z consumers and attracting new users, but did not disclose specific marketing arrangements [34][35] Question: User trends and onboarding process impact - Management discussed the new onboarding process and product updates aimed at increasing user engagement and ARPU, with promising early results [39][40] Question: Advertising outlook for Q3 and beyond - Management indicated strong growth in advertising revenue, particularly in Korea and Japan, while acknowledging the need for foundational work in North America [44][46] Question: Strategy for user-generated content alongside established IP - Management stated that the collaboration with established IP complements the creator ecosystem, enhancing user acquisition and engagement [49][51] Question: Drivers of Q3 revenue growth and sustainability - Management clarified that the Q3 guidance does not include short-term impacts from the Disney collaboration, focusing instead on strong fundamentals in paid content and advertising [55][56] Question: Exclusivity of new original web comic series from Disney - Management expressed excitement about both original and existing series, noting that the collaboration acknowledges Webtoon as a leader in the format [60][62] Question: Advertising business performance excluding Wattpad impact - Management acknowledged the challenges posed by Wattpad but remains optimistic about the long-term potential of the rest of the world advertising market [68]

Financial Data and Key Metrics Changes - Total revenue for Q2 2025 was $12.7 million, a significant increase from $5.2 million in Q2 2024, primarily driven by an $8 million milestone payment from Torii and net YCANT revenue of $4.5 million [22][24] - GAAP net income for Q2 2025 was $200,000 or $0.02 per share, compared to a net loss of $17.2 million or $3.7 per share in Q2 2024 [24] - Non-GAAP net income for Q2 2025 was $2.4 million or $0.25 per share, compared to a net loss of $14.4 million or $3.11 per share in Q2 2024 [24][26] Business Line Data and Key Metrics Changes - The YCANT business reported a record 13,434 dispensed applicator units in Q2 2025, representing a sequential growth of 32.8% over the prior quarter [6][22] - Net YCANT revenue in Q2 2025 was $4.5 million, reflecting shipments to distribution partners, offset by standard gross to net adjustments [22][23] Market Data and Key Metrics Changes - The company is experiencing strong demand for YCANT, particularly in territories with high prevalence of molluscum contagiosum and robust medical and pharmacy benefit coverage [8][12] - Over 1.6 million patients in Japan contract molluscum annually, representing a significant market opportunity for YCANT [19] Company Strategy and Development Direction - The company is focused on expanding its commercial strategy for YCANT, targeting high-value territories and enhancing relationships with healthcare professionals [10][12] - An amended agreement with Torii Pharmaceutical is expected to provide up to $18 million in non-dilutive capital in 2025, strengthening the company's balance sheet [14][15] - The company plans to initiate a global Phase III program for YCANT for the treatment of common warts, with the first patient expected to be dosed in the U.S. in 2025 [18][19] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in generating strong and sustainable growth driven by YCANT's unique product attributes and the relationships built with the medical community [28] - The company anticipates continued growth in the second half of 2025, supported by the ongoing expansion of its sales force and improved access to YCANT [28][44] Other Important Information - The company executed a reverse stock split at a ratio of one for ten shares, impacting the share price [24] - As of June 30, 2025, the company had cash and cash equivalents of $15.4 million, which may not be sufficient to fund operations for the next year without additional capital [26] Q&A Session Summary Question: Expansion of the sales force and reasons for increased YCANT adoption - Management expects to add 5 to 10 more sales representatives in the near term, attributing success to the tenacity of sales reps and strong support from the medical community [32][34] Question: Growth expectations for Q3 and patient access updates - Management noted that molluscum is often diagnosed year-round, and they are seeing increased adoption among pediatricians and dermatologists [43][44] Question: Increase in receivables and gross to net (GTN) changes - The increase in receivables is partly due to collection terms of sixty days, and management has not changed the WACC since launch [47][51]

Journey Medical Corp (DERM) Q2 2025 Earnings Call August 12, 2025 04:30 PM ET Speaker0Ladies and gentlemen, thank you for standing by. Good afternoon and welcome to Journey Medical's Second Quarter twenty twenty five Financial Results and Corporate Update Conference Call. At this time, all participants are in listen only mode. Participants of this call are advised that the audio of this conference call is being broadcast live over the Internet and is also being recorded for playback purposes. A webcast repl ...

Financial Data and Key Metrics Changes - Net revenues decreased by $300,000 or 19% from $1,500,000 for the three months ended June 30, 2024, to $1,200,000 for the three months ended June 30, 2025 [7] - Cost of net revenues increased by $300,000 or 47% from $500,000 for the three months ended June 30, 2024, to $2,800,000 for the three months ended June 30, 2025 [8] - Gross margin decreased to 32% for the three months ended June 30, 2025, from 63% for the three months ended June 30, 2024 [8] Business Line Data and Key Metrics Changes - Service revenue decreased by $700,000, partially offset by an increase of $400,000 in product sales driven by four GS chipset sales [7] - Research and development expenses decreased by $700,000 or 16% from $4,200,000 for the three months ended June 30, 2024, to $3,500,000 for the three months ended June 30, 2025 [9] - General and administrative expenses increased by $600,000 or 20% from $2,900,000 for the three months ended June 30, 2024, to $3,400,000 for the three months ended June 30, 2025 [9] Market Data and Key Metrics Changes - The average selling price of the five GS chipset is expected to be roughly four times that of traditional four GS products [6] Company Strategy and Development Direction - The company is focused on the commercialization of its five GS chipset, with initial samples delivered to lead customers and production expected to commence in the third quarter [4][5] - Collaboration with Iridium Communications and G plus D aims to enhance the five G platform and expand into non-terrestrial network space [5] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about a stronger end of the year as five GS chipset sales are expected to commence soon [6] - The company anticipates operational efficiencies to improve as revenue increases with the transition to five GS product sales [8] Other Important Information - The company ended the quarter with cash and cash equivalents of $1,300,000, net accounts receivable of $3,800,000, and net inventory of $3,000,000 [10] - The company received $11,000,000 in gross proceeds from a registered direct offering, primarily used for five GS chipset sampling and debt retirement [10] Q&A Session Summary - No questions were raised during the Q&A session, and the meeting concluded without any inquiries [14]

Inovio Pharmaceuticals (INO) Q2 2025 Earnings Call August 12, 2025 04:30 PM ET Speaker0Good afternoon, ladies and gentlemen, and welcome to the Inovio Second Quarter twenty twenty five Financial Results Conference Call. At this time, all lines are in listen only mode. Following the presentation, we will conduct a question and answer session. This call is being recorded on Tuesday, 08/12/2025. I would now like to turn the conference over to Jenny Wilson.Please go ahead.Speaker1Good afternoon, and thank you f ...

Intellicheck (IDN) Q2 2025 Earnings Call August 12, 2025 04:30 PM ET Speaker0Greetings, and welcome to the Intellicheck Q2 twenty twenty five Earnings Call. At this time, all participants are in a listen only mode. A brief question and answer session will follow the formal presentation. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Gar Jackson, Investor Relations.Thank you. You may begin.Speaker1Thank you, operator. Good afternoon, and thank you for joining ...